Announcements Trials
Browse Landscape

Phase

Phase 2 7Phase 3 2Phase 1/2 2Phase 1 2

Status

Completed 2Active not recruiting 2Recruiting 1

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 1Breast 1

Conditions

Lymphoma 1Breast Neoplasms 1

Interventions

Paclitaxel 291Gemcitabine 254Carboplatin 253Cisplatin 250Radiotherapy 219Cyclophosphamide 218Irinotecan 184pembrolizumab 180Docetaxel 174Bevacizumab 166Capecitabine 148Nivolumab 141Fluorouracil 132Dexamethasone 125Bortezomib 123Oxaliplatin 115Cytarabine 113Erlotinib Hydrochloride 112Sorafenib 110Temozolomide 109Doxorubicin 106Rituximab 105Leucovorin 105Etoposide 105Filgrastim 99Everolimus 97Lenalidomide 95Ipilimumab 90Pemetrexed 89fludarabine phosphate 84

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Completed × Loperamide × Clear all
NCT03030417 2024-12-10

Indenoisoquinoline LMP744 in Adults With Relapsed Solid Tumors and Lymphomas

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
36 enrolled 35 charts
Lymphoid

Lymphoma

NCT05252546 2022-12-23

Effect of Montmorillonite Power or Loperamide on the Pharmacokinetics of Pyrotinib in Healthy Subjects

Jiangsu HengRui Medicine Co., Ltd.

Phase 1 Completed
36 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡